Advances in Clinical and Experimental Medicine

Adv Clin Exp Med
Impact Factor (IF) – 1.227
Index Copernicus (ICV 2018) – 157.72
MNiSW – 40
Average rejection rate – 84.38%
ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download PDF

Advances in Clinical and Experimental Medicine

2015, vol. 24, nr 4, July-August, p. 585–593

doi: 10.17219/acem/47742

Publication type: original article

Language: English

Download citation:

  • BIBTEX (JabRef, Mendeley)
  • RIS (Papers, Reference Manager, RefWorks, Zotero)

Creative Commons BY-NC-ND 3.0 Open Access

Protective Effects of Molsidomine Against Cisplatin-Induced Nephrotoxicity

Habib T. E. Karakoc1,A,B,C,D,E,F, Ramazan Altintas2,A,B,C,D,E,F, Hakan Parlakpinar3,A,D,E,F, Alaaddin Polat4,B,C, Emine Samdanci5,B,C, Mustafa Sagir3,B,C, Zeynep R. Duran4,B,C

1 Student, Medical Faculty, Inonu University, Malatya, Turkey

2 Department of Urology, Medical Faculty, Inonu University, Malatya, Turkey

3 Department of Physiology, Medical Faculty, Inonu University, Malatya, Turkey

4 Department of Pharmacology, Medical Faculty, Inonu University, Malatya, Turkey

5 Department of Pathology, Medical Faculty, Inonu University, Malatya, Turkey

Abstract

Background. Cisplatin, an effective chemotherapeutic agent, is used for the treatment of several types of cancers. However, cisplatin has some severe side effects such as nephrotoxicity. On the other hand, molsidomine, a NO donor, has anti-oxidative and vasodilator effects.
Objectives. The aim of this study was to estimate the protective effects of molsidomine on cisplatin-induced nephrotoxicity.
Material and Methods. Thirty-two rats were randomly divided into 4 groups as follows: (1) control; (2) received a single-dose intraperitoneal (i.p.) injection of 5 mg/kg cisplatin; (3) received single i.p. dose of molsidomine (4 mg/kg/day) for 3 consecutive days before cisplatin treatment; (4) received single i.p. dose of molsidomine (4 mg/kg/day) for 3 consecutive days. The specific biochemical markers, including antioxidants, and the histopathological alterations were evaluated.
Results. Cisplatin significantly increased malondialdehyde (MDA) and myeloperoxidase (MPO) levels and decreased glutathione peroxidase (GPX) level. Molsidomine significantly decreased MPO level nearly to control level; however, its ameliorating effects on MDA, SOD, CAT and GPX did not reach to significant levels. Cisplatin-induced elevation of blood-urea-nitrogen and serum-creatinine were diminished after molsidomine administration. Cisplatin also induced severe tubular degeneration, nuclear condensation, apoptosis and scattered patchy inflammation in the histological examination. Molsidomine improved all of these histological damages.
Conclusion. In this study, the beneficial effect of molsidomine against cisplatin nephrotoxicity has been evaluated for the first time.

Key words

cisplatin, molsidomine, kidney, rat.

References (62)

  1. Baek SM, Kwon CH, Kim JH, Woo JS, Jung JS, Kim YK: Differential roles of hydrogen peroxide and hydroxyl radical in cisplatin-induced cell death in renal proximal tubular epithelial cells. J Lab Clin Med 2003, 142, 178–186.
  2. Lajolo PP, De Camargo B, Del Giglio A: Omission of day 2 of antiemetic medications is a cost saving strategy for improving chemotherapy-induced nausea and vomiting control: results of a randomized phase III trial. Am J Clin Oncol 2009, 32, 23–26.
  3. Maines MD: Effect of cisplatinum on heme, drug, and steroid metabolism pathways: possible involvement in nephrotoxicity and infertility. Crit Rev Toxicol 1990, 21, 1–20.
  4. Masubuchi Y, Horie T: Toxicological significance of mechanism-based inactivation of cytochrome p450 enzymes by drugs. Crit Rev Toxicol 2007, 37, 389–412.
  5. Kuhad A, Pilkhwal S, Sharma S, Tirkey N, Chopra K: Effect of curcumin on inflammation and oxidative stress in cisplatin-induced experimental nephrotoxicity. J Agric Food Chem 2007, 55, 10150–10155.
  6. Santos NA, Bezerra CS, Martins NM, Curti C, Bianchi ML, Santos AC: Hydroxyl radical scavenger ameliorates cisplatin-induced nephrotoxicity by preventing oxidative stress, redox state unbalance, impairment of energetic metabolism and apoptosis in rat kidney mitochondria. Cancer Chemother Pharmacol 2008, 61, 145–155.
  7. Ajith TA, Nivitha V, Usha S: Zingiberofficinale Roscoe alone and in combination with a tocopherol protect the kidney against cisplatin-induced acute renal failure. Food Chem Toxicol 2007, 45, 921–927.
  8. Atessahin A, Yilmaz S, Karahan I, Ceribasi AO, Karaoglu A: Effects of lycopene against cisplatin-induced nephrotoxicity and oxidative stress in rats. Toxicology 2005, 212, 116–123.
  9. Sun Y: Free radicals, antioxidant enzymes and carcinogenesis. Free Radic Biol Med 1990, 8, 583–599.
  10. Satoh M, Kashihara N, Fujimoto S, Horike H, Tokura T, Namikoshi T, Sasakı T, Makıno H: A novel free radical scavenger, edarabone, protects against cisplatin-induced acute renal damage in vitro and in vivo. J Pharmacol Exp Ther 2003, 305, 1183–1190.
  11. Sueishi K, Mishima K, Makino K, Itoh Y, Tsuruya K, Hirakata H, Oishi R: Protection by a radical scavenger edaravone against cisplatin-induced nephrotoxicity in rats. Eur J Pharmacol 2002, 451, 203–208.
  12. Tsuruya K, Tokumoto M, Ninomiya T, Hirakawa M, Masutani K, Taniguchi M, Fukuda K, Kanai H, Hirakata H, Iida M: Antioxidant ameliorates cisplatin-induced renal tubular cell death through inhibition of death receptor-mediated pathways. Am J Physiol Renal Physiol 2003, 285, 208–218.
  13. Bohn H, Schönafinger K: Oxygen and oxidation promote the release of nitric oxide from sydnonimines. J Cardiovasc Pharmacol 1989, 14, 6–12.
  14. Hinz B, Schröder H: The nitric oxide donor SIN-1 is free of tolerance and maintains its cyclic GMP stimulatory potency in nitrate-tolerant LLC-PK1 cells. Pharm Res 1999, 16, 633–636.
  15. Valdivielso JM, Blantz RC: Acute renal failure: is nitric oxide the bad guy? Antioxid Redox Signal 2002, 4, 925–934.
  16. Rabb H, O’Meara YM, Maderna P, Coleman P, Brady HR: Leucocytes, cell adhesion molecules and the ischemic acute renal failure. Kidney Int 1997, 51, 1463–1468.
  17. Kubes P, Suzuki M, Granger DN: Nitric oxide: An endogenous modulator of leukocyte adhesion. Proc Natl Acad Sci USA 1991, 88, 4651–4655.
  18. Sato E, Simpson KL, Grisham MB, Koyama S, Robbins RA: Inhibition of MIP-1alpha-induced human neutrophil and monocyte chemotactic activity by reactive oxygen and nitrogen metabolites. J Lab Clin Med 2000, 135, 161–169.
  19. Johnson G 3rd, Tsao PS, Lefer AM: Cardioprotective effects of authentic nitric oxide in myocardial ischemia with reperfusion. Crit Care Med 1991, 19, 244–252.
  20. Chander V, Chopra K: Effect of molsidomine and l-arginine in cyclosporine nephrotoxicity: role of nitric oxide. Toxicology 2005, 207, 463–474.
  21. Gupta A, Sharma S, Chopra K: Reversal of iron-induced nephrotoxicity in rats by molsidomine, a nitric oxide donor. Food Chem Toxicol 2008, 46, 537–543.
  22. Colak C, Parlakpınar H: Hayvan Deneyleri: In Vivo Denemeler in Bildirimi: ARRIVE Kılavuzu-Derleme. J Turgut Ozal Med Cent 2012, 19, 128–131.
  23. Bokemeyer C, Fels LM, Dunn T, Voigt W, Gaedeke J, Schmoll HJ, Stolte H, Lentzen H: Silibinin protects against cisplatin-induced nephrotoxicity without compromising cisplatin or ifosfamide anti-tumour activity. Br J Cancer 1996, 74, 2036–2041.
  24. Parlakpinar H, Sahna E, Ozer MK, Ozugurlu F, Vardi N, Acet A: Physiological and pharmacological concentrations of melatonin protect against cisplatin-induced acute renal injury. J Pineal Res 2002, 33, 161–166.
  25. Ozturk K, Ozyurt H, Somay A, Karaca C: The effects of nitric oxide donor molsidomine on skeletal muscle damage in a rat hind limb model of ischemia-reperfusion. Eur Surg Res 2009, 42, 71–77.
  26. Uchiyama M, Mihara M: Determination of malonaldehyde precursor in tissues by tiobarbituric acid test. Anal Biochem 1978, 34, 271–278.
  27. Sun Y, Oberley LW, Li Y: A simple method for clinical assay of superoxide dismutase. Clin Chem 1988, 34, 497–500.
  28. Aebi H: Catalase; in Bergmeyer HU editor. Methods of enzymatic analysis. New York Academic Press 1974, 673–677.
  29. Paglia DE, Valentine WN: Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidase. J Lab Clin Med 1967, 70, 158–170.
  30. Wei H, Frenkel K: Relationship of oxidative events and DNA oxidation in Sencar mice to in vivo promoting activity of phorbol ester-type tumor promoters. Carcinogenesis 1993, 14, 1195–1201.
  31. Begg EJ, Barclay ML: Aminoglycisides – 50 years on. Br J Clin Pharmacol 1995, 39, 597–603.
  32. Fatima S, Yusufi AN, Mahmood R: Effect of cisplatin on renal brush border membrane enzymes and phosphate transport. Hum Exp Toxicol 2004, 23, 547–554.
  33. Mahmood I, Waters DH: A comparative study of uranyl nitrate and cisplatin induced renal failure in rat. Eur J Drug Metab Pharmacol 1994, 19, 327–336.
  34. Yao X, Panichpisal K, Kurtzman N, Nugent K: Cisplatin nephrotoxicity: a review. Am J Med Sci 2007, 334, 115–124.
  35. Chirino YI, Pedraza-Chaverri J: Role of oxidative and nitrosative stress in cisplatin-induced nephrotoxicity. Exp Toxicol Pathol 2009, 61, 223–242.
  36. Baliga R, Zhang Z, Baliga M, Ueda N, Shah SV: In vitro and in vivo evidence suggesting a role for iron in cisplatininduced nephrotoxicity. Kidney Int 1998, 53, 394–401.
  37. Nath KA, Norby SM: Reactive oxygen species and acute renal failure. Am J Med 2000, 109, 665–678.
  38. Altintas R, Parlakpinar H, Beytur A, Vardi N, Polat A, Sagir M, Odabas GP: Protective effect of dexpanthenol on ischemia-reperfusion-induced renal injury in rats. Kidney Blood Press Res 2012, 36, 220–230.
  39. Khan R, Khan AQ, Qamar W, Lateef A, Tahir M, Rehman MU, Ali F, Sultana S: Chrysin protects against cisplatin-induced colon toxicity via amelioration of oxidative stress and apoptosis: probable role of p38MAPK and p53. Toxicol Appl Pharmacol 2012, 258, 315–329.
  40. Chirino YI, Trujillo J, Sanchez-Gonzalez DJ, Martínez-Martínez CM, Cruz C, Bobadilla NA, Pedraza-Chaverri J: Selective iNOS inhibition reduces renal damage induced by cisplatin. Toxicol Lett 2008, 176, 48–57.
  41. Ikari A, Nagatani Y, Tsukimoto M, Harada H, Miwa M, Takagi K: Sodium-dependent glucose transporter reduces peroxynitrite and cell injury caused by cisplatin in renal tubular epithelial cells. Biochim Biophys Acta 2005, 1717, 109–117.
  42. Chander V, Chopra K: Renal protective effect of molsidomine and L-arginine in ischemia-reperfusion induced injury in rats. J Surg Res 2005, 128, 132–139.
  43. Rodriguez-Peña A, Garcia-Criado FJ, Eleno N, Arevalo M, Lopez-Novoa JM: Intrarenal administration of molsidomine, a molecule releasing nitric oxide, reduces renal ischemia-reperfusion injury in rats. Am J Transplant 2004, 4, 1605–1613.
  44. Chirino YI, Orozco-Ibarra M, Pedraza-Chaverri J: Evidencias de laparticipacio´n del peroxinitrito en variasenfermedades. Rev Invest Clin 2006, 58, 350–358.
  45. Chang B, Nishikawa M, Sato E, Utsumi K, Inoue M: L-Carnitine inhibits cisplatin-induced injury of the kidney and small intestine. Arch Biochem Biophys 2002, 405, 55–64.
  46. Koc A, Duru M, Ciralik H, Akcan R, Sogut S: Protective agent, erdosteine, against cisplatin-induced hepatic oxidant injury in rats. Mol Cell Biochem 2005, 278, 79–84.
  47. Valentovic MA, Ball JG, Brown JM, Terneus MV, McQuade E, Van Meter S, Hedrick HM, Roy AA, Williams T: Resveratrol attenuates cisplatin renal cortical cytotoxicity by modifying oxidative stress. Toxicol In Vitro 2014, 28, 248–257.
  48. Nasr AY, Saleh HA: Aged garlic extract protects against oxidative stress and renal changes in cisplatin-treated adult male rats. Cancer Cell Int 2014, 14, 92.
  49. Ademiluyi AO, Oboh G, Agbebi OJ, Oyeleye SI: Dietary inclusion of sorghum (Sorghum bicolour) straw dye protects against cisplatin-induced nephrotoxicity and oxidative stress in rats. Pharm Biol 2014, 52, 829–834.
  50. Iseri S, Tavsu F, Saglam B, Ercan F, Gedik N, Yegen B: Social isolation stress in the early life reduces the severity of colonic inflammation. Marmara Med J 2006, 19, 65–72.
  51. Zhao K, Chen C, Shi Q, Deng W, Zuo T, He X, Liu T, Zhao L, Wang W: Inhibition of glycogen synthase kinase-3β attenuates acute kidney injury in sodium taurocholate-induced severe acute pancreatitis in rats. Mol Med Rep 2014, 10, 3185–3192.
  52. Punuru P, Sujatha D, Kumari BP, Charisma VV: Evaluation of aqueous extract of Murraya koenigii in unilateral renal ischemia reperfusion injury in rats. Indian J Pharmacol 2014, 46, 171–175.
  53. Grisham MB: Interaction between nitric oxide and superoxide: Role in modulating leukocyte adhesion in the postischemic microvasculature. Transplant Proc 1995, 27, 2842.
  54. Matés JM: Effects of antioxidant enzymes in the molecular control of reactive oxygen species toxicology. Toxicology 2000, 153, 83–104.
  55. Mukherjee S, Banerjee SK, Maulik M, Dinda AK, Talwar KK, Maulik SK: Protection against adriamycin-induced cardiotoxicity by garlic: role of endogenous antioxidants and inhibition of TNF-a expression. BMC Pharmacol 2003, 3, 16.
  56. Gaetani GF, Ferraris AM, Rolfo M, Mangerini R, Arena S, Kirkman HN: Predominant role of catalase in the disposal of hydrogen peroxide within human erythrocytes. Blood 1996, 87, 1595–1599.
  57. Karthikeyan K, SaralaBai BR, Devaraj SN: Cardio-protective effect of grape seed proanthocyanidins on isoproterenol-induced myocardial injury in rats. Int J Cardiol 2007, 115, 326–333.
  58. Ran Q, Liang H, Ikeno Y, Qi W, Prolla TA, Roberts LJ 2nd, Wolf N, Van Remmen H, Richardson A: Reduction in glutathione peroxidase increases life span through increased sensitivity to apoptosis. J Gerontol Biol Sci Med Sci 2007, 62, 932–942.
  59. Sahu BD, Rentam KK, Putcha UK, Kuncha M, Vegi GM, Sistla R: Carnosic acid attenuates renal injury in an experimental model of rat cisplatin-induced nephrotoxicity. Food Chem Toxicol 2011, 49, 3090–3097.
  60. Davis CA, Nick HS, Agarwal A: Manganese superoxide dismutase attenuates cisplatin-induced renal injury: importance of superoxide. J Am Soc Nephrol 2001, 12, 2683–2690.
  61. Ozkol H, Musa D, Tuluce Y, Koyuncu I: Ameliorative influence of Urticadioica L against cisplatin-induced toxicity in mice bearing Ehrlich ascites carcinoma. Drug Chem Toxicol 2012, 35, 251–257.
  62. Al-Kharusi N, Babiker HA, Al-Salam, Waly MI, Nemmar A, Al-Lawati I, Yasin J, Beegam S, Ali BH: Ellagic acid protects against cisplatin-induced nephrotoxicity in rats: a dose-dependent study. Eur Rev Med Pharmacol Sci 2013, 17, 299–310.